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Introduction
In 1995, approximately 1 million new cases of
gastric cancer were found worldwide. Currently, it is
the fourth leading cause of death from cancer in Hong
Kong. The cause of gastric cancer is still unclear but
it is generally considered a multifactorial process that
may include dietary factors, environmental factors, and
bacterial and viral infections. Several large clinical
trials are trying to address the causal relationship
between Helicobacter pylori infection and gastric
cancer. This article summarises the epidemiology of
gastric cancer and the relationship between gastric
cancer and Helicobacter pylori infection.
The epidemiology of gastric cancer
Until recently, gastric cancer was the most frequently
diagnosed cancer in the world. About 1 million new
cases were diagnosed worldwide in 1995, of which
75% occurred in Asia. Countries in Asia with a high
incidence include Japan, China, and South Korea; those
with a low incidence include India, Pakistan, and Thai-
land. Other high-incidence areas include the former
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Gastric cancer is the second most common fatal malignant neoplasm in the world. In mainland China,
gastric cancer is now the second most common malignant neoplasm, while in Hong Kong the mortality
rate ranked fourth of all cancers in 1995. Dietary factors seem to be involved in gastric carcinogenesis,
and beta carotene, selenium, and vitamin E (tocopherols) have been shown to help reduce gastric cancer
mortality. Prospective case-control studies have shown an increased risk for the development of gastric
cancer of between 2.8 and 6.0 among carriers of Helicobacter pylori. In addition, cagA-positive strains of
Helicobacter pylori have been found to be associated with gastric cancer and duodenal ulceration. The
exact role of Helicobacter pylori in gastric carcinogenesis is still being investigated. Helicobacter pylori
eradication programmes to help prevent gastric cancer are being conducted in China and other parts of
the world. In high-risk areas such as China, a combination approach that includes Helicobacter pylori
eradication and dietary supplementation may be necessary.
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Soviet Union, tropical South America, the Carribean,
and southern Europe. There is no consistent pattern.
Furthermore, there are considerable differences in
incidence within a country. Several regions of China
such as Changle in Fujian  have a very high incidence
of gastric cancer, while in some parts, the incidence
is quite low.1 Even in small countries such as Japan,
there is also considerable variation in the incidence
and mortality rate.2 An observation that is consistent
in high- and low-risk areas, however, is that the
incidence of gastric cancer increases with age. In
Japan, the incidence of gastric cancer in 1981 was
82.8 per 100 000 for men aged 45 to 49 years but
572.1 per 100 000 for men aged 85 years or older.3
The male to female ratio in terms of incidence is
usually from 1.5:1 to 3.0:1 worldwide while in China,
it varies from 1.6:1 to 3.9:1.4
Gastric cancer has been associated with low socio-
economic status, based on family income,5 education,6
or occupation.7 Generally, the risk of gastric cancer
developing among individuals from the lower socio-
economic class is up to two times that of those from
the upper socio-economic class. There is also an asso-
ciation between H pylori infection and low socio-
economic status.8 Familial studies have found that the
risk of gastric cancer developing in relatives of patients
with gastric cancer is increased two- to three-fold.9
Since family members usually share the same environ-
ment and have a similar socio-economic status, how-
ever, it is difficult to exclude environmental factors.
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There is now evidence from epidemiological studies
that H pylori carriers have a significantly greater risk
for the development of gastric cancer. Results from
three prospective epidemiological studies10-12 estimate
that H pylori carriers have a 2.8- to 6.0-fold increased
risk of gastric cancer developing over mean follow-up
periods of 6 to 16 years when compared with their
H pylori–negative counterparts. The overall mean risk
was calculated to be 3.8.13 This odds ratio increased
to 8.7 in those who were diagnosed 15 years or more
after testing positive for H pylori. A significant trend
towards an increased odds ratio arises with an increased
length of follow-up.13 Six of nine case-control studies
from various countries have demonstrated a signifi-
cantly increased risk for the development of gastric
cancer among H pylori carriers while the remaining
studies did not show any differences.14-22 In addition,
other studies have demonstrated a significant correla-
tion between the H pylori infection rates and the
incidence of gastric cancer.23-31 Two studies from
China27,30 have shown an unequivocal association
between gastric cancer mortality rates and H pylori
infection rates. A previous study by us also showed
that the prevalence of H pylori infection is higher in
Changle province than in Hong Kong, with the gastric
cancer mortality rate in Changle being about 10 times
that of Hong Kong.28
The odds ratio of having gastric cancer is increased
in young patients who are infected with H pylori.
Kikuchi et al32 have shown that at the average age of
34 years, the odds ratio for an H pylori carrier to have
gastric cancer is 13.3.
There have been reports that gastric cancer mortal-
ity rates bear an inverse relationship to duodenal ulcer
disease rates and to the duodenal ulcer to gastric ulcer
ratio.33-35 It remains a puzzle why the same organism
could cause two diseases and yet one disease seems
to protect against the other. The pathogenesis of the
two diseases seems so different that each is likely to
involve a mutually exclusive pathway. Hence, some
factors in addition to H pylori are probably involved
in the determination of ulcer or cancer formation.
In 1994, the Working Group of the International
Agency for Research on Cancer, in affiliation with the
World Health Organization, concluded that H pylori is
carcinogenic to humans and classified it as a group 1
carcinogen.36 It remains unclear at this stage what
other factors are involved in H pylori–associated
gastric carcinogenesis. Infection with the organism
leads to changes in many factors that are important
in the pathogenesis of gastric cancer, including the
vitamin C level in gastric juice, reactive oxygen
metabolites, and epithelial cell proliferation. Specific
pathogenic H pylori strains have been incriminated
as responsible. Blaser et al37 have demonstrated that
cagA-positive H pylori patients have a greater risk
for the development of intestinal metaplasia and gas-
tric cancer. Furthermore, CagA-producing H pylori
strains are consistently found to be more prevalent
in patients with peptic ulceration38-42 and, to a certain
extent, in patients with gastric cancer.43,44 In a con-
trolled study, Parsonnet et al44 found that subjects
infected with cagA-positive strains had a nearly
six-fold increase in the incidence of gastric cancer
compared with uninfected individuals, whereas those
who had been infected with cagA-negative strains
had only a marginally (and insignificantly) increased
risk of developing gastric cancer compared with the
uninfected controls. Unfortunately, two other case-
control studies that were performed in areas with high
gastric cancer rates and high background prevalence
of cagA-positive strains45,46 did not support this find-
ing. Thus, whether or not cagA-positive strains are
relevant in the development of gastric cancer is still
debatable.
Intervention trials investigating the
prevention of gastric cancer
Although diet is an important factor in gastric carcino-
genesis, no intervention trials involving diet and gas-
tric cancer are in progress and none are planned.
There are, however, four micronutrient supplementa-
tion studies that have a cancer other than gastric
cancer as the end-point that we can refer to. The
Linxian chemoprevention trial on oesophageal cancer
conducted in China showed a borderline significant
reduction in the incidence of gastric cancer and
mortality rates in a group that was given selenium,
beta carotene, and vitamin E.47 Another study in China
showed a slightly higher incidence and mortality rate
of gastric cancer in the group receiving 14 vitamins
and 12 minerals compared with the placebo group.48
A Finnish chemoprevention trial that investigated
lung cancer gave participants either alpha tocopherol
(alpha tocopheryl acetate), beta carotene, both, or a
placebo. The investigators discovered that the incidence
of gastric cancer was slightly greater among men who
took beta carotene compared with those not receiving
it, and likewise for those who took alpha tocopherol
compared with those not receiving it; however, these
differences were not statistically significant.49 A fourth
trial included 22 000 male physicians in the United
States and involved supplementation with beta
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carotene or placebo. No difference in the incidence of
gastric cancer was found.50
The initial chemoprevention trials were all based
on high-risk subjects—namely, those with precancer-
ous lesions in the stomach. The end-point used was
regression or progression of the precancerous lesions.
There have been three large-scale chemoprevention
trials of this type (Table 1). The Columbian study
was designed so that subjects (with chronic atrophic
gastritis, intestinal metaplasia, or dysplasia) were given
H pylori eradication therapy and then randomised to
receive either beta carotene and vitamin C (ascorbic
acid) or placebo (Correa P, written communication,
1999). Another study in Venezuela randomised sub-
jects (with chronic atrophic gastritis, intestinal meta-
plasia, or dysplasia) to receive either vitamin C, beta
carotene, and vitamin E, or placebo.51 The European
Cancer Prevention/Intestinal Metaplasia Study Group
randomised patients who had intestinal metaplasia
to receive H pylori eradication therapy, followed by
vitamin C supplementation or placebo.52
Other chemoprevention trials follow asymptomatic
subjects to see if the eradication of H pylori reduces the
overall incidence of gastric cancer. The end-point will be
cancer incidence among the cohort. There are currently
three chemoprevention trials using this approach to
study asymptomatic H pylori carriers (Table 2). Our
group was the first to use such a study design.28
A total of 1600 asymptomatic carriers are part of
a study being conducted in Changle, Fujian province,
China. Participants were randomised to receive
H pylori eradication therapy or placebo in 1994
without micronutrient supplements.28 The effect on
cancer incidence and any precancerous lesions will
be investigated by a second upper endoscopy in late
1999 in Changle. Two other studies in Shandong,
China also have a similar design and aim to establish
whether or not cancer is prevented by the eradication
of H pylori.53,54
There are now at least two more intervention
trials looking at precancerous lesions and another trial
using cancer incidence as an end-point. Scrutinising
cancer incidence in this way will give conclusive
evidence that H pylori causes gastric cancer, assum-
ing that the results of these trials are positive. Unfor-
tunately, all of these trials are conducted in areas with
high incidences of gastric cancer. It is possible that
apart from H pylori, there are important dietary and
environmental factors that also contribute to gastric
carcinogenesis. It would thus be reasonable to add
micronutrient supplementation to H pylori eradication
therapy to maximise the protective effect, although sup-
plementation will almost certainly require more than
one micronutrient. With the results of these trials
becoming available in the next few years, we may be
able to devise some strategies to prevent the world’s
second most common cancer.
Table 1. Intervention trials in progress that include follow-up of precancerous lesions
Country/region Disease No. of Study Treatment Length of
present participants design follow-up
Columbia CAG†, IM‡, 700 2x2; (1) Triple therapy 6 years
(Correa,* 1991) dysplasia placebo (2) beta carotene + vitamin C
Venezuela CAG, IM, 2200 Double-blind; Vitamin C + vitamin E 3 years
(Munoz et al,51 1992) dysplasia placebo +beta carotene
Europe IM 1200 Double-blind; (1) Triple therapy 3 years
(Read and Johnston,52 1993) placebo (2) Vitamin C
* Correa P, written communication, 1999†
 CAG chronic atrophic gastritis‡
 IM intestinal metaplasia
Table 2. Intervention trials in progress that have the development of cancer as their end-point
Country/region H pylori No. of Study Treatment Length of
status participants design follow-up
Changle +ve 1600 Placebo Triple therapy 5 years
(Wong et al,28 1994)
Shandong +ve 1000 Placebo Triple therapy 5 years
(Sung et al,53 1996)
Shandong +ve 3411 Placebo 23 factorial of: 5 years
(Gail et al,54 1995) (1) Triple therapy
(2) Vitamin
     and mineral supplement
(3) Garlic supplement
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